In one of the clinical trials, SELECT, patients who were treated with semaglutide experienced a 20-28% reduction in major adverse cardiovascular events (MACE) nonfatal myocardial infarction (MI), nonfatal stroke, and cardiovascular death
10.1007/s10103-015-1814-6
Morroniside ameliorates glucocorticoid-induced osteoporosis and promotes osteoblastogenesis by interacting with sodium-glucose cotransporter 2
Raadsma, P
Patients prescribed GLP-1 drugs may differ in important ways, including overall health, access to care and concurrent treatments, that could influence outcomes
While extensive data reassure their use, more trials are needed, particularly for populations like children, older adults, and those with severe illness